INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of Sana Biotechnology, Inc. (SANA) Investors – Holzer & Holzer, LLC Encourages Investors With Significant Losses to Contact the Firm

Core Viewpoint - A shareholder class action lawsuit has been filed against Sana Biotechnology, alleging misleading statements and failure to disclose material facts regarding the company's financial health and product prospects [1]. Group 1: Allegations in the Lawsuit - The lawsuit claims that Sana was at significant risk of having insufficient funds to maintain its current operations and advance its product candidates [1]. - It is alleged that the product candidates SC291 in oncology, SC379, and SG299 were less promising than what the company had communicated to investors [1]. - The lawsuit suggests that to preserve cash and focus on more promising candidates, Sana was likely to decrease funding for or discontinue SC291, SC379, and SG299, as well as significantly reduce its workforce [1]. - Consequently, the defendants are accused of overstating Sana's financial capacity to sustain operations and advance existing product candidates [1].